PR··Consumer Discretionary
Broadridge's Distributed Ledger Repo Processes $7.6 Trillion in October
October 2026 ADV reaches $345 billion as Broadridge continues to advance institutional tokenization infrastructure
Press Releases
Delayed 3mFastest customizable press release feed in the world.
Signed out · Sign up for real-time
Updates arrive automatically.
Broadridge's Distributed Ledger Repo Processes $7.6 Trillion in October MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. PR··Health CareMHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.
Approval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kgJoenja is expected to become available to patients covered by the expanded indication in February 2027Marks another step in Pharming’s strategy to expand Joenja across age groups and international markets Leiden, the Netherlands, November 6, 2026: Pharming (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has approved an extension of the marketing authorization of Joenja®, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, to include c
Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026 PR··Health CareMolecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026
Logic-gated Switch-DARPin design enables potent, selective cytotoxicity against cells co-expressing tumor-associated antigens (TAAs) previously considered undruggable for T cell engagersFavorable safety profile, with new data indicating healthy tissues expressing either TAA remain intactAttractive therapeutic window underlines MP0632’s readiness for IND-enabling studies in solid tumors co-expressing MSLN and
Kyivstar releases 3Q26 results, raises outlook PR··TelecommunicationsKyivstar releases 3Q26 results, raises outlook
Key highlights Revenue rose 17.5% YoY to USD 349 mn (UAH 15.6 bn, +26.5%). Telecommunications and infrastructure revenue grew 8.4% (UAH +16.7%) on higher mobile ARPU and data usage. Digital revenue grew 68.9% (UAH +81.8%) to 21.7% of total revenue.EBITDA rose 10.3% YoY to USD 189 mn (UAH 8.4 bn, +18.7%), a 54.0% margin. The telecommunications and infrastructure margin was 57.7%; the digital margin was 40.7%. Net profit was USD 99 mn and diluted EPS USD 0.36, compared with a net loss of USD 89 mn in 3Q25. 3Q25 reflected a one-time, non-cash charge of USD 162 mn recognized in 3Q25 results related to the Kyivstar listing. Capex fell 25.6% YoY to USD 66 mn. LTM capex intensity declined to 24.0%
Can One Man Save the World? Possibly! PR··Consumer DiscretionaryCan One Man Save the World? Possibly!
Gaia Acquires Exclusive Streaming Rights to Gabe Polsky's The Man Who Saves the World? Executive Produced by Peter Farrelly and Danny McBride An ancient Indigenous prophecy, a spiritual leader on a mission, and an unlikely journey into the Amazon collide in a documentary that asks one of humanity's biggest questions.
Fermi's Co-Founder and Largest Shareholder, Toby Neugebauer: "Fermi's Shareholders, the Markets and Texas Voters Have Rejected Rick Perry and Fermi's 'We Can Do Whatever We Want' Board" PR··Real EstateFermi's Co-Founder and Largest Shareholder, Toby Neugebauer: "Fermi's Shareholders, the Markets and Texas Voters Have Rejected Rick Perry and Fermi's 'We Can Do Whatever We Want' Board"
"Today should be Fermi's greatest day. Fermi was built on the understanding that voters do not want data centers on their grid. Fermi's stock should be soaring, as Fermi was designed specifically to protect Americans by supplying AI companies with private power, using private water and private transmission.""Fewer than four in ten total outstanding Fermi shares voted for Rick Perry. Set aside the Perry family's own shares, and it was barely three in ten.""The board was also a victim of its own bylaw changes.""We suspended our proxy campaign four months ago, when Fermi stock was more than five times today's closing price. Fermi's problems are not with us. Instead of pointing the blame outward
INOVIO Announces Pricing of Approximately $75 Million Public Offering PR··Health CareINOVIO Announces Pricing of Approximately $75 Million Public Offering
INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 58,747,235 shares of its common stock at a public offering price of $1.05 per share of common stock and pre-funded warrants to purchase 12,681,337 shares of common stock at an offering price of $1.049 per pre-funded warrant, in each case before underwriting discounts and commissions. INOVIO also granted the underwriters an option for a period of 30 days to purchas
Orchestra BioMed Announces Pricing of Public Offering PR··Health CareOrchestra BioMed Announces Pricing of Public Offering
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, announced today the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $5.00 per share (the "Offering"). In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the
Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer PR··Health CareJohnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1First advancement in the second-line treatment setting for recurrent or metastatic head and neck cancer in a decade, bringing a new subcutaneous option to patients with significant unmet need2-3 Extending its well-established, dual-targeted benefit beyond lung cancer, RYBREVANT FASPRO™ targets both EGFR and MET pathways – two key drivers of tumor progression in head and neck cancer2
Ambarella Announces Third Quarter Fiscal Year 2027 Earnings Conference Call to be Held November 24, 2026 PR··TechnologyAmbarella Announces Third Quarter Fiscal Year 2027 Earnings Conference Call to be Held November 24, 2026
Ambarella, Inc. (NASDAQ:AMBA), an edge AI semiconductor company, today announced it will hold its third quarter fiscal year 2027 earnings conference call on Tuesday, November 24, 2026 at 1:30 p.m. (Pacific Time). The company will issue its earnings release after the market closes that same day. Those interested in asking a question on the call are required to register online in advance. Upon completing the first step of the online registration process, please note a registration verification code will be emailed to you, and this code must be entered to complete the online registration process. Once registered and verified, the dial-in
Dover Announces Pricing Terms, Expiration and Results of Cash Tender Offers for Certain of Its Outstanding Debt Securities PR··IndustrialsDover Announces Pricing Terms, Expiration and Results of Cash Tender Offers for Certain of Its Outstanding Debt Securities
Dover (NYSE:DOV), a diversified global manufacturer, today announced the pricing terms, expiration and results of its previously announced tender offers (each, a "Tender Offer" and together, the "Tender Offers") to purchase for cash up to an aggregate purchase price, excluding the Accrued Coupon Payment (as defined below), of $300,000,000 (the "Tender Cap"), of the debt securities referred to below (collectively, the "Notes," and each, a "Series" of Notes), in the order of Acceptance Priority Levels set forth in the table below and subject to proration. Each Tender Offer has been made upon the terms and subject to the conditions set f
Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs PR··Health CarePerspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs
Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across multiple patient populationsPreliminary evidence of more robust anti-tumor activity and durable responses in GEP-NET patients whose target lesions all express SSTR2+ supports focusing on this populationBamzireotide continues to be well-tolerated Targeting End-of-Phase 2 meeting in 1Q 2027
Cannae Holdings, Inc. Announces Reduction in the Size of Its Board of Directors to Ten Members PR··Consumer DiscretionaryCannae Holdings, Inc. Announces Reduction in the Size of Its Board of Directors to Ten Members
~ Woodrow Tyler and Mark Linehan will not Stand for Re-election at Cannae’s 2026 Annual Meeting of Shareholders ~ Cannae Holdings, Inc. (NYSE:CNNE) ("Cannae" or the "Company") today announced that Woodrow ("Woody") Tyler and Mark Linehan each notified the Board of Directors that they will not stand for re-election at Cannae’s December 11, 2026 Annual Meeting of Shareholders. "On behalf of the Board, we thank Woody and Mark for their service to Cannae," Douglas K. Ammerman, Chairman of Cannae’s Board of Directors, commented. "Woody and Mark have brought significant experience and valuable perspectives to our Board, and we appreciate the work they have done in helping drive Cannae’s strat
FirstService Residential Selected to Manage Scarlett Place Condominium in Baltimore PR··FinanceFirstService Residential Selected to Manage Scarlett Place Condominium in Baltimore
FirstService Residential, the leading residential community management company, is pleased to announce that it has been selected to provide full-service property management services for Scarlett Place Condominium, one of Baltimore's most distinctive luxury residential communities. Located overlooking Baltimore's Inner Harbor at the intersection of Harbor East and Little Italy, Scarlett Place is renowned for its Mediterranean-inspired architecture, stunning views of the harbor and skyline, and the unique integration of an original wall from the historic Scarlett Seed Factory. The upscale h
NHC Announces Common Dividend PR··Health CareNHC Announces Common Dividend
National HealthCare Corporation (NYSE:NHC), the nation’s oldest publicly traded long-term health care company, announced today that it will pay a quarterly dividend of 67 cents per common share to shareholders of record on December 31, 2026, and payable on January 29, 2027. Forward-Looking StatementsStatements in this press release that are not historical facts are forward-looking statements. NHC cautions investors that any forward-looking statements made involve risks and uncertainties and are not guarantees of future performance. The risks and uncertainties are detailed from time to time in reports filed by NHC with the S.E.C., including Forms 8-K, 10-Q and 10-K, and include, among others,
BCP Investment Corporation to Postpone Third Quarter 2026 Earnings Release and Conference Call PR··FinanceBCP Investment Corporation to Postpone Third Quarter 2026 Earnings Release and Conference Call
BCP Investment Corporation (NASDAQ:BCIC) ("BCIC" or "the Company") today announced that it is postponing its Third Quarter 2026 financial results release and conference call, originally scheduled for November 5, 2026 and November 6, 2026, respectively. The delay allows management additional time to finalize the financial disclosures, regulatory filings, and structural terms related to a potential strategic initiative. Management believes delaying the earnings release is prudent to ensure the market receives comprehensive information regarding both quarterly performance and the total financial impact of the potential strategic initiative simultan
Nuvve Appoints Two Independent Directors to Help Rebuild the Company and Support Its Return to a National Securities Exchange PR··IndustrialsNuvve Appoints Two Independent Directors to Help Rebuild the Company and Support Its Return to a National Securities Exchange
New independent directors bring public-company experience in corporate strategy, capital markets and investor relations Nuvve Holding Corp. (OTCQB:NVVE), a global leader in the future of flexible energy by turning batteries, electric vehicles (EVs), buildings, and distributed assets into dynamic grid resources, today announced the appointment of Antonie Wobbe Ploegsma and Andrew J. Ritter to its Board of Directors as independent directors. The two bring experience in corporate strategy, corporate finance, capital markets and investor relations as Nuvve rebuilds its financial foundation, strengthens its governance and works to regain a listing on a national securities exchange. "Wobbe an
Ventas Announces Pricing of Senior Notes Offering PR··Real EstateVentas Announces Pricing of Senior Notes Offering
Ventas, Inc. (NYSE:VTR) ("Ventas" or the "Company") announced today that its wholly owned subsidiary, Ventas Realty, Limited Partnership ("Ventas Realty"), has priced an underwritten public offering of $500.0 million aggregate principal amount of 5.500% Senior Notes due 2033 (the "Notes") at an issue price equal to 99.441% of the principal amount of the Notes. The Notes will be senior unsecured obligations of Ventas Realty and will be fully and unconditionally guaranteed by the Company and will mature on December 15, 2033. The sale of the Notes is expected to close on November 10, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the proceeds fr
TKO Announces Pricing of Senior Secured Notes Offering PR··Consumer DiscretionaryTKO Announces Pricing of Senior Secured Notes Offering
TKO Group Holdings, Inc. (NYSE:TKO) ("TKO" or the "Company"), a premium sports and entertainment company, today announced the pricing of the previously announced offering (the "Offering") of $1.0 billion million in aggregate principal amount of 6.500% Senior Secured Notes due 2031 (the "notes") by its indirect subsidiary, TKO Worldwide Holdings, LLC ("TKO Worldwide"). The closing of the Offering is expected to occur on or about November 13, 2026, subject to customary closing conditions.TKO Worldwide expects to use the net proceeds from the Offering for general corporate purposes, which may include making distributions to its parent entities to fund share repurchases under TKO’s previously an
Energy Transfer LP Announces Pricing of $2.7 Billion of Senior Notes PR··Public UtilitiesEnergy Transfer LP Announces Pricing of $2.7 Billion of Senior Notes
Energy Transfer LP (Texas Stock Exchange, TXSE: ET) today announced the pricing of its offering of $900 million aggregate principal amount of 5.450% senior notes due 2032, $900 million aggregate principal amount of 5.900% senior notes due 2037 and $900 million aggregate principal amount of 6.550% senior notes due 2057 (together, the "senior notes") at prices to the public of 99.972%, 99.719% and 99.862%, respectively, of their face value. The sale of the senior notes is expected to settle on November 20, 2026, subject to the satisfaction of customary closing conditions. Energy Transfer intends to use the net proceeds of approximately $2.68 billion (before offering expenses) to refinance e